Autopsy report · NCT01843738

Radiation Use During Vemurafenib Treatment

“Competing Trials”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

University of Utah

Sponsor type

University, hospital or other

Conditions

BRAFV600 Mutation; Stage IV Melanoma

Interventions

Radiation therapy; Vemurafenib

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Focused Ultrasound for the Treatment of Pancreatic Cancer - an International Registry
  “Competing trial will publish similar results” (71% match in meaning)
• A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder
  “Competing studies” (68% match in meaning)
• Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
  “the study was closed early due to competing trials” (66% match in meaning)
• Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
  “Due to Competing Studies” (63% match in meaning)
• Using Ultrasound to Predict the Results of Draining Pleural Effusions
  “Difficult to recruit to due to conflicting trials recruiting similar participants.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.